Please Scroll Down to See Forums Below
napsgear
genezapharmateuticals
domestic-supply
puritysourcelabs
UGL OZ
UGFREAK
napsgeargenezapharmateuticals domestic-supplypuritysourcelabsUGL OZUGFREAK

Deca post cycle........

lol
 
No test because of the sides OLOLLOLOLOLOLLLLLLLLLLLLLLLL

Deca can wreck your cawk
and make you have biggah booobs than MM69
 
wrong forum. i moved it to the AS forum for you.

for those who posted before me with smartass answers, next time, just tell the guy it's the wrong forum, or tell a mod.

or don't make any threads asking why you're not a mentor/mod. thanks.
 
By Jenetic (First Sticky in the PCT forum)

When to begin PCT:

On average, begin PCT approximately 5-10 days after your last injection regardless of longer acting esters. Begin PCT 1-3 days after your last injection and/or intake when using short acting esters.

Keep in mind, pituitary LH secretion automatically increases as the hormones diminish from your system. The elevated androgen levels are from an exogenous source and your endogenous production is suppressed. Therefore, waiting for the exogenous androgens to completely clear from your system, ultimately results in lower total concentrations of androgens in your system when beginning PCT. This leads to an unfavorable andgrogen:estrogen ratio and the well known “crash” effect.

*As previously mentioned, the actions of HCG take place independently and is not affected by exogenous hormones and/or preexisting HPTA suppression. There are no contradictions with respect to the effectiveness of HCG usage while exogenous hormones are present in your system.

PCT Protocol(s):

1.) 1,000 IUs HCG 3x/wk (mon/wed/fri) in combination with 20 mgs Nolvadex ED for the first 3 weeks. After, discontinue HCG and continue with 20 mgs Nolvadex ED for an additional 3 weeks.

2.) 1,000 IUs HCG 3x/wk (mon/wed/fri) in combination with 20 mgs Nolvadex ED and 50 mgs Clomid ED for the first 3 weeks. After, discontinue HCG and continue with 20 mgs Nolvadex ED and 50 mgs Clomid ED for an additional 3 weeks.

3.) 1,500 IUs HCG 3x/wk (mon/wed/fri) in combination with 20 mgs Nolvadex ED for the first 3 weeks. After, discontinue HCG and continue 20 mgs Nolvadex ED for an additional 3 weeks.

4.) 1,500 IUs HCG 3x/wk (mon/wed/fri) in combination with 100 mgs Clomid ED and 20 mgs Nolvadex ED for the first 3 weeks. After, discontinue HCG and continue with 50 mgs Clomid ED and 20 mgs Nolvadex ED for an additional 3 weeks.

Option one can be considered as a standard PCT protocol. This should apply to all basic cycles. Option 2 is generally the same as option one except for the addition of Clomid which is added as a supporting recovery aid. Option three and four incorporate a higher HCG dosage and have a relationship similar to options one and two in the sense that Clomid is incorporated in the latter as a supporting recovery aid
 
i WAS ALWAYS UNDER THE IMPRESSION THAT DEPENDING ON THE GEAR USED YOUR PCT CHANGED WITH THAT COMPOUND IE NOT USING NOLVADEX FOR PCT WHEN YOU CYCLED DECA OR ANY OTHER 19-NOR DRUG OR DO I HAVE THAT RIGHT????
 
i WAS ALWAYS UNDER THE IMPRESSION THAT DEPENDING ON THE GEAR USED YOUR PCT CHANGED WITH THAT COMPOUND IE NOT USING NOLVADEX FOR PCT WHEN YOU CYCLED DECA OR ANY OTHER 19-NOR DRUG OR DO I HAVE THAT RIGHT????
i just recently read that to...never before in last few years did anyone mention it...im using nolva for pct right now after a tren cycle...so far no problems or issues
 
its ok if the 19-nor compound is out of your system.
basically, nolva up regulates the progesterone receptor, meaning that using nolva whilst the compound is still in your system can increase the risk and severity of any progesterone induced side effects.
some people get away with it, others grow leaky breasts.
 
Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?
U Karck, F Kommoss
European Journal of Cancer
September 2000 (Vol. 36, Issue , Pages 45-46)

Abstract
We studied the expression of oestrogen and progesterone receptors (ER, PR) in postmenopausal women receiving tamoxifen for breast cancer. In addition the literature addressing the question of ER and PR expression in breast tissue during treatment with tamoxifen was reviewed. We demonstrated consistent expression of ER and PR in endometria from patients receiving tamoxifen, with a trend towards a higher proportion of receptor positive specimens during tamoxifen. In breast cancer tissue, the ER content seemed to be reduced following tamoxifen treatment. After short time exposure to tamoxifen, the PR appeared to be increased, longer treatment caused the PR to go down to pretreatment levels or below.
 
Top Bottom